Patents by Inventor Dean Sheppard

Dean Sheppard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECONFIGURABLE DASHBOARD WITH MOVEABLE MODULES
    Publication number: 20260178180
    Abstract: An example operation may include one or more of logging in a device with a software application, displaying a dashboard of the software application on the device, wherein the dashboard comprises a plurality of movable display modules with different display content enclosed therein, respectively, receiving a command via the dashboard to reconfigure a position of a movable display module within the dashboard from among the plurality of movable display modules, and modifying the position of the movable display module to a different position within the dashboard based on position information included in the received command to generate a reconfigured dashboard.
    Type: Application
    Filed: February 13, 2026
    Publication date: June 25, 2026
    Applicant: The Toronto-Dominion Bank
    Inventors: Andrew Peart, Dean Sheppard, Geeth Bandi, Prasad Koila, Gaurav Rajderkar
  • Reconfigurable dashboard with moveable modules
    Patent number: 12566541
    Abstract: An example operation may include one or more of logging in a device with a software application, displaying a dashboard of the software application on the device, wherein the dashboard comprises a plurality of movable display modules with different display content enclosed therein, respectively, receiving a command via the dashboard to reconfigure a position of a movable display module within the dashboard from among the plurality of movable display modules, and modifying the position of the movable display module to a different position within the dashboard based on position information included in the received command to generate a reconfigured dashboard.
    Type: Grant
    Filed: September 7, 2023
    Date of Patent: March 3, 2026
    Assignee: The Toronto-Dominion Bank
    Inventors: Andrew Peart, Dean Sheppard, Geeth Bandi, Prasad Koila, Gaurav Rajderkar
  • Method of treating cancer using anti-AV8 antibodies
    Patent number: 12371499
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: July 29, 2025
    Assignees: The Regents of the University of California, Pfizer, Inc.
    Inventors: Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
  • PREVENTION OF POSTERIOR CAPSULAR OPACIFICATION (PCO) WITH INTEGRIN AVB8 BLOCKING ANTIBODY
    Publication number: 20250002587
    Abstract: Methods to treat or prevent posterior capsular opacification (PCO) using antibodies that inhibit ?v?8 ligand adhesion are provided.
    Type: Application
    Filed: January 25, 2022
    Publication date: January 2, 2025
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The University of Delaware
    Inventors: Dean Sheppard, Scott Bidlingmaier, Bin Liu, Amha Atakilit, Melinda K. Duncan, Mahbubul H. Shihan
  • COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH AVB8 INTEGRIN
    Publication number: 20240425601
    Abstract: Compositions and methods comprising integrin ?8 antibodies are provided.
    Type: Application
    Filed: January 25, 2022
    Publication date: December 26, 2024
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dean Sheppard, Scott Bidlingmaier, Bin Liu, Amha Atakilit
  • INHIBITORS OF ALPHA-5 BETA-1 INTEGRIN AND USES THEREOF
    Publication number: 20240409527
    Abstract: Described herein, inter alia, are alpha-5 beta-1 inhibitors, pharmaceutical compositions including alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.
    Type: Application
    Filed: October 3, 2022
    Publication date: December 12, 2024
    Inventors: Dean Sheppard, William F. DeGrado, Hyunil Jo, Aparna Sundaram
  • Inhibitors of alpha 2 beta 1 integrin and methods of use thereof
    Patent number: 11643388
    Abstract: Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: May 9, 2023
    Assignees: The Regents of the University of California, ShangPharma Innovation Inc.
    Inventors: Dean Sheppard, William F. DeGrado, Aparna Sundaram, Hyunil Jo, Richard Beresis, Marc Adler
  • Inhibitors of integrin alpha 2 beta 1 and methods of use
    Patent number: 11597727
    Abstract: Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: March 7, 2023
    Assignee: The Regents of the University of California
    Inventors: Dean Sheppard, Aparna Sundaram, William F. DeGrado, Hyunil Jo
  • INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF
    Publication number: 20220411366
    Abstract: Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.
    Type: Application
    Filed: April 30, 2021
    Publication date: December 29, 2022
    Inventors: Dean Sheppard, William F. DeGrado, Aparna Sundaram, Hyunil Jo, Richard Beresis, Marc Adler
  • Alpha-5 beta-1 inhibitors
    Patent number: 11530180
    Abstract: The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: December 20, 2022
    Assignees: The Regents of the University of California, Shanghai ChemPartner Co., Ltd.
    Inventors: Dean Sheppard, William F. DeGrado, Hyunil Jo, Aparna Sundaram, Richard Beresis
  • Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin
    Patent number: 11492406
    Abstract: Methods and compositions comprising integrin ?8 antibodies are provided.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: November 8, 2022
    Assignee: The Regents of the University of California
    Inventors: Dean Sheppard, Amha Atakilit, Neil Cowan Henderson
  • ANTI-AVBETA8 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
    Publication number: 20220289850
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 15, 2022
    Applicants: PFIZER INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
  • Anti-AVB8 antibodies and compositions and uses thereof
    Patent number: 11359024
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: June 14, 2022
    Assignees: PFIZER INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akhurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
  • BIOMARKERS FOR USE IN INTEGRIN THERAPY APPLICATIONS
    Publication number: 20220049301
    Abstract: The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with ?v?6 integrin inhibition or therapy with TGF-? pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against ?v?6-integrin and/or TGF-? pathway inhibitors.
    Type: Application
    Filed: March 2, 2021
    Publication date: February 17, 2022
    Applicants: Biogen MA Inc., The Regents of the University of California
    Inventors: Shelia M. Violette, Dean Sheppard
  • INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE
    Publication number: 20210387986
    Abstract: Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.
    Type: Application
    Filed: March 13, 2019
    Publication date: December 16, 2021
    Inventors: Dean Sheppard, Aparna Sundaram, William F. DeGrado, Hyunil Jo
  • ALPHA-5 BETA-1 INHIBITORS
    Publication number: 20210171455
    Abstract: The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 10, 2021
    Inventors: Dean Sheppard, William F. DeGrado, Hyunil Jo, Aparna Sundaram, Richard Beresis
  • Inhibitors of integrin alpha 5 beta 1 and methods of use
    Patent number: 10836720
    Abstract: Disclosed herein, inter alia, are inhibitors of integrin alpha 5 beta 1 and methods of using the same.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: November 17, 2020
    Assignee: The Regents of the University of California
    Inventors: Dean Sheppard, Aparna Sundaram, William F. Degrado, Hyunil Jo, Joel McIntosh
  • BIOMARKERS FOR USE IN INTEGRIN THERAPY APPLICATIONS
    Publication number: 20200248257
    Abstract: The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with ?v?6 integrin inhibition or therapy with TGF-? pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against ?v?6-integrin and/or TGF-? pathway inhibitors.
    Type: Application
    Filed: November 14, 2019
    Publication date: August 6, 2020
    Applicants: Biogen MA Inc., The Regents of the University of California
    Inventors: Shelia M. Violette, Dean Sheppard
  • METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH ALPHA-V BETA-8 INTEGRIN
    Publication number: 20200247891
    Abstract: Methods and compositions comprising integrin ?8 antibodies are provided.
    Type: Application
    Filed: February 14, 2020
    Publication date: August 6, 2020
    Inventors: Dean Sheppard, Amha Atakilit, Neil Cowan Henderson
  • Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin
    Patent number: 10597455
    Abstract: Methods and compositions comprising integrin ?8 antibodies are provided.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: March 24, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dean Sheppard, Amha Atakilit, Neil Cowan Henderson